Research Article

Correction of endothelial dysfunction by type II inhibitors and tadalafil in rats Ivan C. Koklin*, Mikhail V. Pokrovskiy, Lyudmila М. Danilenko, Konstantin S. Trunov, Anton P. Danilenko, Vladislav O. Soldatov, Natalia N. Bystrova, Natalia N. Bunatyan

ABSTRACT

Background: Endothelial dysfunction (ED) is one of the most cardiovascular disease pathogenesis leaders. This fact discloses a large number of potential molecular targets for novel pharmacological drugs. Among these targets, enzymes arginase type II and phosphodiesterase type 5 can be distinguished. Materials and Methods: The study included 120 male Wistar rats weighting 250–300 g, which were randomly divided into 12 equal groups. The screening was carried out among compounds with laboratory codes C239–0844, L207–0208, L207–0210, L207–0322, L207–0404, L207–0525, and L327–0346. N-nitro- L- methyl ether (L-NAME)-induced ED was modeled by daily intraperitoneal injection of L-NAME at a dose of 25 mg/kg to male rats for 7 days. The degree of coefficient of ED (CED) was determined on the 8th day from the beginning of the experiment. In parallel, a test was performed for adrenoreactivity and myocardial reserve exhaustion, as well as an assessment of the values of biochemical markers (total [NO] and endothelial NO synthase [eNOS] expression). Results and Discussion: Compounds L207–0525 and L327–0346 at a dose of 1 mg/kg showed the highest activity and were showing the values of CED 1.5 ± 0.3 and 1.9 ± 0.4 c.u., respectively, whereas in the control, it was 5.4 ± 0.4 c.u. At the same time, studied compounds showed cardioprotective effect, what expressed in adrenoreactivity decrease and myocardial reserve exhaustion, as well as a lowering of NO metabolites (NOx) values and expression of eNOS. The combined use of tadalafil and arginase II inhibitors increased the endothelioprotective effect but did not enhance the cardioprotective effect. Conclusion: The study proved the possibility of arginase inhibitors using to prevent the ED development. Among arginase II inhibitors, the most promising compounds are L207–0525 and L327–0346. KEY WORDS: Arginase II inhibitors, Endothelial dysfunction, N-nitro-L-arginine methyl ether, Tadalafil

BACKGROUND They catalyze the same biochemical reactions but differ in sites of tissue expression. There are many A large number of accumulated studies demonstrate studies confirming the relationship of arginase the relationship between endothelial dysfunction increased activity with the development of ED in [1] (ED) and cardiovascular diseases. A number of various vascular and heart diseases. The decrease studies have convincingly shown that an increase in the arginase activity leads to gain of nitric oxide in arginase activity leads to the development of (NO) production and due to this positive effect on [2] ED in experimental models of hypertension, the vascular function. The necessity to use arginase [3] [4] [5] atherosclerosis, diabetes, and aging. It was inhibitors to increase NO synthesis and prevent the established that arginase is an enzyme of the urea development of ED becomes obvious.[6,7] cycle, which is highly active, thousands of times higher than that of endothelial NO synthase (eNOS). Arginase inhibitors can be selective and nonselective. In the human organism, arginase is presented in L-norvaline is the most studied of the non-selective the two isoforms: Arginase I is the hepatic form arginase inhibitors.[8,9] However, its effectiveness and arginase II is the extrahepatic form, most often does not fully meet the requirements of clinical localized in the kidneys, prostate, and small intestine. practice. In this regard, it seems appropriate to search for compounds with high cardio- and endothelio- Access this article online protective activity among various pharmacological groups of promising endothelioprotectors[10-17] Website: jprsolutions.info ISSN: 0975-7619 including selective arginase II inhibitors.[18-20]

Department of Pharmacology and Clinical Pharmacology, Medical Institute, Belgorod State University, 85, Pobedy St., Belgorod 308015, Russia

*Corresponding author: Ivan C. Koklin, Department of Pharmacology and Clinical Pharmacology, Medical Institute, Belgorod State National Research University, 85, Pobedy St., Belgorod 308015, Russia. E-mail: [email protected]

Received on: 13-07-2019; Revised on: 15-08-2019; Accepted on: 19-09-2019

Drug Invention Today | Vol 12 • Issue 11 • 2019 2731 Ivan C. Koklin, et al.

MATERIALS AND METHODS to its molecular weight, as compared with the tap proteins. The film was dried in air, the strips were Animals scanned, and the AUC was calculated using the total The study included 120 adult male Wistar rats laboratory program. weighting 250–300 g. The animals were kept in a standard conventional vivarium in individually The level of NO metabolites (the total concentration ventilated cages (Tecniplast, USA). Twelve hours of and , NOx) was determined by a before the experiment, animals were deprived of access colorimetric method for the development of color to feed and randomly divided into 12 equal groups in in the diazotization reaction of sulfanilamide , accordance with the type of pharmacotherapy. which is a part of the Griess reagent. To construct a calibration curve, a 1 M solution of NaNO2 in water Procedures was used, which was stored at −20°C; before use, it N-nitro-L-arginine methyl ether (L-NAME)-induced was diluted 1000 times and a series of dilutions were NO deficiency was simulated by injecting L-NAME prepared to construct a curve. daily for 7 days once a day, intraperitoneally, at a Statistical Assay dose of 25 mg/kg. Then, the animals were taken in an experiment for the quantification of the coefficient The data were checked for normal distribution. The of ED (CED), as described previously.[21] In brief, type of distribution was determined by the criterion of the common carotid artery was catheterized and Shapiro–Wilk test. In the case of a normal distribution, connected to a pressure transducer (Biopac Systems, the mean value (M) and standard error of the mean USA). Then, a solution of acetylcholine at a dose of (m) were calculated. In cases of non-parametric 40 µg/kg (endothelium-dependent vasodilation) and a distribution, the median (Me) and quartile range were solution of at a dose of 30 µg/kg calculated. Intergroup differences were analyzed (endothelium-dependent vasodilatation) were injected by Dunnett’s test or Mann–Whitney U-test with into the femoral vein. The area under curve (AUC) Bonferroni correction test, depending on the type of of the pressure drop in response to nitroprusside distribution. Statistical analysis was performed using divided by the AUC of pressure drop in response to Statistica 10.0 software. acetylcholine was taken as CED. RESULTS AND DISCUSSION Testing the myocardium function due to the evaluation Arginase II inhibitors moderately reduced blood of adrenoreactivity and myocardial reserve was carried pressure (BP) and CED. Compounds L207–0525 out as described before.[22] and L327–0346 showed the highest activity in a Western Blot and Biochemical Assay dose of 1 mg/kg, where the values of CED were 1.5 ± 0.3 c.u. and 1.9 ± 0.4 c.u., against 5.4 ± 0.4 c.u. The level of eNOS expression was determined in in control group. The combined use of tadalafil a cell lysate, as previously described.[23] After the (0.1 mg/kg) and compounds L207–0525 and L327– incubation, cell was washed 3 times with 5 mM 0346 has a protective effect, preventing a CED phosphate buffer. The cells from one well were increase and lowering BP [Table 1]. collected in 100 μl of lysis buffer, centrifuged for 10 min at 1000 g, and subjected to polyacrylamide At the same time, the compounds attenuated L-NAME- gel electrophoresis. Each plate was applied a mixture induced heart injury, lowering the adrenoreactivity, of pre-stained protein markers with a molecular increasing the myocardial reserve as well as the values weight range (Mm) 7000–200,000 Yes (Bio-Rad of the NOx and eNOS expression [Tables 2 and 3]. Kaleidoscope Prestained Standards, USA). At the end of electrophoresis, the proteins were transferred It is known that pharmacological inhibition of arginase from the gel to a nitrocellulose membrane – Western activity can potentially have a beneficial effect in a blot (60 V, 1 h). After washing the membrane 3 times number of pathological cardiovascular diseases.[24] The with 5 mM phosphate buffer pH 7.4, containing therapeutic effect of arginase inhibition was investigated 150 mM NaCl and 0.05% Tween-200, it was treated in many experimental models of cardiovascular overnight with a solution of polyclonal rabbit diseases with positive results. There are clinical antibodies against human eNOS (BD Transduction studies where arginase inhibitors were studied through Laboratories, USA) diluted (ratio=1:500). Then, cutaneous microdialysis in patients with ischemic heart the membrane was washed and incubated for an disease and type 2 diabetes mellitus[25] and heart failure hour with diluted at a ratio of 1:300 secondary and hypertension.[26] These observations suggest that antibodies conjugated with horseradish peroxidase arginase activity gain is important in the development (goat anti-rabbit IgG antibodies, Sigma, USA). The of human cardiovascular diseases. An important strip corresponding to eNOS was detected according limitation of currently available arginase inhibitors is

2732 Drug Invention Today | Vol 12 • Issue 11 • 2019 Ivan C. Koklin, et al.

Table 1: Effect of selective arginase II inhibitors (1 mg/kg) and tadalafil (0.1 mg/kg) on the hemodynamic parameters in animals with modeling L-NAME-induced endothelial dysfunction (M±m; n=10) Animal group Systolic BP (mmHg) Diastolic BP (mmHg) CED (c.u.) Intact 150.8±3.3 110.6±5.1 1.1±0.1 Control 206.4±4.0* 134.8±5.3* 5.4±0.4* L-NAME+С239–0844 187.4±2.2 139.7±2.3 2.8±0.3# L-NAME+L207–0208 179.3±2.4 130.2±3.2 2.3±0.3# L-NAME+L207–0210 180.3±3.0 128.1±5.4 2.7±0.3# L-NAME+L207–0322 175.2±2.9 125.5±3.8 2.5±0.3# L-NAME+L207–0404 180.3±4.4 132.5±5.4 2.9±0.3# L-NAME+L207–0525 174.1±3.5 128.2±4.0 1.5±0.3# L-NAME+L327–0346 170.4±4.2 120.3±3.7 1.9±0.4# L-NAME+tadalafil 143.6±5.0 120.8±4.1 2.0±0.4# L-NAME+tadalafil+L207–0525 159.7±3.2 119.3±3.8 1.3±0.3# L-NAME+tadalafil +L327–0346 160.8±2.7 124.9±5.1 1.2±0.3# *: Significant difference with the group of intact animals (P<0.05). #: Significant difference with the L-NAME group induced by endothelial dysfunction (P<0.05), BP: Blood pressure, CED: Coefficient of endothelial dysfunction, L-NAME: N-nitro-L-arginine methyl ether

Table 2: The effect of arginase II selective inhibitors and tadalafil on the contractility indicators dynamics during stress tests in animals with L-NAME-induced endothelial dysfunction (M±m; n=10) Animal group Adrenoreactivity (mmHg) Exhaustion of myocardial reserve (%) Intact 199.2±7.1 83.6±4.3 Control 246.3±6.0* 66.7±3.9* L-NAME+С239–0844 234.3±5.9* 72.4±4.7* L-NAME+L207–0208 228.6±6.9* 74.3±5.2* L-NAME+L207–0210 236.3±5.7* 79.4±4.5* L-NAME+L207–0322 220.3±6.1* 76.6±3.3* L-NAME+L207–0404 231.3±7.3* 70.1±3.5* L-NAME+L207–0525 212.3±8.1# 83.2±4.9# L-NAME+L327–0346 213.4±4.2# 81.3±4.7# L-NAME+tadalafil 211.7±7.5# 80.6±5.3# L-NAME+tadalafil+L207–0525 200.4±6.7# 85.5±6.3# L-NAME+tadalafil+L327–0346 201.2±4.2# 87.2±5.9# *: Significant difference with the group of intact animals (P<0.05), #: Significant difference with the L-NAME group induced by endothelial dysfunction (P<0.05), L-NAME: N-nitro-L-arginine methyl ether that they have little or no selectivity for arginase II. Table 3: The effect of arginase II selective inhibitors Therefore, the study of selective inhibitors of arginase and tadalafil on the dynamics of the biochemical II is of undoubted interest. marker values (total NO and eNOS expression) in animals with L-NAME-induced endothelial Tadalafil is the least studied selective competitive dysfunction (M±m; n=10) inhibitor of phosphodiesterase 5 (PDE5), which Animal group NOх (µmol/l) eNOS (%) preventing the destruction of cyclic guanosine Intact 121.5±10.4 5.4±0.2 monophosphate (cGMP), enhances the vasodilating Control 82.1±9.4* 2.05±0.3* effect of NO, and thereby can improve the state L-NAME+С239–0844 98.5±8.9* 2.4±0.2* [1] L-NAME+L207–0208 90.6±9.9* 2.3±0.3* of vascular endothelial function. The study L-NAME+L207–0210 96.3±9.7* 2.4±0.2* of PDE5 inhibitors and arginase II inhibitors L-NAME+L207–0322 99.3±8.1* 2.6±0.1* cardiopharmacology may make it possible to L-NAME+L207–0404 97.3±8.3* 2.1±0.2* L-NAME+L207–0525 124.3±8.7# 4.2±0.2# determine qualitatively new indications for the use of L-NAME+L327–0346 121.4±9.2# 4.3±0.1 these drugs. L-NAME+tadalafil 128.7±8.5# 4.9±0.3# L-NAME+tadalafil 134.4±9.7# 5.5±0.2# Studied in this research compounds as monotherapy did +L207–0525 # # not lead to normalization of BP values and, therefore, L-NAME+tadalafil 135.2±8.8 5.9±0.3 +L327–0346 did not completely prevent vascular wall hypertrophy. *NOx–the final NOx metabolites, eNOS expression, *: Significant The fact that pharmacological inhibition of arginase difference with the group of intact animals (P<0.05), L-NAME: N-nitro-L- activity corrects a defect in the production of NO in arginine methyl ether tissues in diabetes mellitus and erectile dysfunction[5] prompted us to investigate the combined effects on initial BP numbers in the modeling of L-NAME- the systemic cardiovascular effects of drugs that affect induced arterial hypertension were significantly erectile dysfunction of vascular genesis. lower than in the tadalafil monotherapy groups, L207–0525 and L327–0346, and this suggests that With the combined use of the investigated the endothelioprotective efficacy of the proposed compounds, selective arginase II inhibitors, the combination is the effect on two different pathogenetic

Drug Invention Today | Vol 12 • Issue 11 • 2019 2733 Ivan C. Koklin, et al. links. On the one hand, tadalafil as PDE5 inhibitor inflammation in mice with allergic airway disease, in association restores the adrenergic system functioning and with increases in protein S-nitrosylation and tyrosine nitration. J Immunol 2008;181:4255-64. promotes the activation of NO synthase, increasing 9. Korokin MV, Pokrovskii MV, Kochkarov VI, Gudyrev OS, the synthesis of cGMP and protein kinase G -1 activity Korokina LV, Pokrovskaya TG, et al. Endothelial and cardio (cGMP-dependent protein kinase). On the other protective effects of , L-norvaline, hand, selective inhibitors of arginase II inhibit the L-arginine and their combinations by simulation of hyperhomo- cysteine induced endothelial dysfunction. Res J Pharm Biol enzyme that destroys the substrate for the formation Chem Sci 2014;5:1375-9. of NO and, due to this, compensate its production 10. Pokrovskiĭ MV, Pokrovskaia TG, Gureev VV, Barsuk AA, level in the endothelium.[7,27-29] Thus, L207–0525 Proskuriakova EV, Korokin MV, et al. Correction of endothelial and L327–0346 monotherapy and tadalafil showed dysfunction by L-arginine under experimental pre-eclampsia conditions. Eksp Klin Farmakol 2012;75:14-6. endothelioprotective properties in inferior combined 11. Shakhno E, Savitskaya T, Pokrovskaya T, Yakushev V, use of these drugs. The more pronounced effects of the Pokrovskii M, Grinshpan D. Use of L-arginine immobilised on combined use of the studied substances are associated activated carbon for pharmacological correction of endothelial with the cumulative capabilities of this combination. disfunction. Res Results Pharmacol 2016;2:30-5. 12. Korokin MV, Pokrovsky MV, Novikov OO, Gureev VV, L207–0525 and L327–0346 increase the availability of Denisyuk TA, Korokina LV, et al. Effect of L-arginine, vitamin endogenous stocks of L-arginine for NO synthase and B6 and folic acid on parameters of endothelial dysfunction also increases the activity of this enzyme. Moreover, and microcirculation in the placenta in modeling of L-NAME- the introduction of a PDE5 inhibitor regulates the induced NO deficiency. Bull Exp Biol Med 2011;152:70-2. 13. Chernomortseva ES, Pokrovskiĭ MV, Pokrovskaia TG, signaling pathways leading to the activation of eNOS Artiushkova EB, Gureev VV. Experimental study of and activates the pathway of NO-cGMP. cardioprotective and endothelioprotective action of macrolides and azalides. Eksp Klin Farmakol 2009;72:29-31. Thus, the combined use of a PDE5 inhibitor and 14. Molchanova O, Pokrovskaya T, Povetkin S, Reznikov K. new compounds from the group of selective arginase Endothelioprotective property of the combination of the thioctic II inhibitor to achieve pronounced endothelium acid and rosuvastatin shown in the endothelial dysfunction models. Res Results Pharmacol 2016;2:9-15. protective effects can be considered more rational. 15. Denisuk TA, Pokrovskii MV, Philippova OV, Dolzhikov AA, Pokrovskaia TG, Korokin MV, et al. Endothelio and CONCLUSION cardioprotective effects of HMG-CoA reductase inhibitors under the condition of endotoxin-induced endothelial Selective inhibition of arginase II has dysfunction. Res J Pharm Biol Chem Sci 2015;6:1542-7. 16. Provotorov V, Korokin M, Pokrovskii M, Povetkin S, endothelioprotective activity and can potentially Lazareva G, Stepchenko A, et al. Endothelio and have a beneficial effect in a number of pathological cardioprotective effects of vitamin В6 and folic acid in cardiovascular diseases. The combination with PDE5 modelling methionine-induced hyperhomocysteinemia. Res inhibitor tadalafil is the most promising combination Results Pharmacol 2016;2:16-19. 17. Ragulina V, Kostina D, Dovgan A, Burda Y, Nadezhdin S. for the correction of ED. Nuclear factor kappa b as a potential target for pharmacological correction endothelium-associated pathology. Res Results REFERENCES Pharmacol 2017;3:114-24. 18. Pokrovskii MV, Korokin MV, Kudryavtsev KV, 1. Johnson FK, Johnson RA, Peyton KJ, Durante W. Arginase Pokrovskaya TG, Gudyrev OS, Gureev VV, et al. Study of inhibition restores arteriolar endothelial function in dahl rats endothelial protective activity of phenol-derived thrombin and with salt-induced hypertension. Am J Physiol Regul Integr arginase-2 inhibitors KUD-259 and KUD-974. Bull Exp Biol Comp Physiol 2005;288:R1057-62. Med 2017;163:436-8. 2. Michell DL, Andrews KL, Chin-Dusting JP. Endothelial 19. Ivlitskaya I, Korokin M, Loktionov A. Pharmacological dysfunction in hypertension: The role of arginase. Front Biosci efficiency of statins and L-norvalin at an endotoxin-induced (Schol Ed) 2011;3:946-60. endothelial dysfunction. Res Results Pharmacol 2016;2:25-35. 3. Ryoo S, Lemmon CA, Soucy KG, Gupta G, White AR, 20. Rajkumar DS, Gudyrev O, Faitelson A, Stepchenko A, Nyhan D, et al. Oxidized low-density lipoprotein-dependent Dolzhikov A, Povetkin S. Study of the influence of endothelial arginase II activation contributes to impaired nitric L-norvaline, rosuvastatin and their combination on the level oxide signaling. Circ Res 2006;99:951-60. of microcirculation in bone tissue in experimental osteoporosis 4. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, and fractures on its background. Res Results Pharmacol Bartoli M, et al. Diabetes-induced coronary vascular 2016;2:20-4. dysfunction involves increased arginase activity. Circ Res 21. Soldatov VO, Malorodova TN, Pokrovskaya TG, 2008;102:95-102. Pokrovskii MV, Kulchenkova TI, Ksenofontov AO. Ultrasonic 5. Santhanam L, Christianson DW, Nyhan D, Berkowitz DE. dopplerography for the evaluation of endothelial function in the Arginase and vascular aging. J Appl Physiol (1985) conduct of pharmacological vascular samples in an experiment. 2008;105:1632-42. Int J Res Pharm Sci 2018;9:735-40. 6. Ash DE. Structure and function of arginases. J Nutr 22. Yakushev V, Filippenko N, Kizilova I, Korokin M, 2004;134:2760S-2764S. Beskhmelnitsyna E, Litvinova A. Research dose dependent 7. Prieto CP, Krause BJ, Quezada C, San Martin R, Sobrevia L, endothelio and cardioprotective activity of selective arginase Casanello P, et al. Hypoxia-reduced II inhibitor in hyperhomocysteine induced endothelial activity is partially explained by higher arginase-2 activity and dysfunction. Res Results Pharmacol 2016;2:42-5. cellular redistribution in human umbilical vein endothelium. 23. Denisyuk T, Lazareva G, Provotorov V, Pokrovskaya T. Placenta 2011;32:932-40. Endothelium and cardioprotective effects of HMG-Co-A- 8. Ckless K, Lampert A, Reiss J, Kasahara D, Poynter ME, reductase in combination with L-arginine in endothelial Irvin CG, et al. Inhibition of arginase activity enhances dysfunction modeling. Res Results Pharmacol 2016;2:4-8.

2734 Drug Invention Today | Vol 12 • Issue 11 • 2019 Ivan C. Koklin, et al.

24. Quitter F, Figulla HR, Ferrari M, Pernow J, Jung C. Increased generating system from a medicinal chemistry perspective: arginase levels in heart failure represent a therapeutic target Current trends and therapeutic options in cardiovascular to rescue microvascular perfusion. Clin Hemorheol Microcirc disease. Pharmacol Ther 2010;126:279-300. 2012;126:2943-50. 28. Bagnost T, Ma L, da Silva RF, Rezakhaniha R, Houdayer C, 25. Holowatz LA, Kenney WL. Up-regulation of arginase activity Stergiopulos N, et al. Cardiovascular effects of arginase contributes to attenuated reflex cutaneous vasodilatation in inhibition in spontaneously hypertensive rats with fully hypertensive humans. J Physiol 2007;581:863-72. developed hypertension. Cardiovasc Res 2010;87:569-77. 26. Kim NN, Cox JD, Baggio RF, Emig FA, Mistry SK, Harper SL, 29. Ryoo S, Gupta G, Benjo A, Lim HK, Camara A, Sikka G, et al. Probing erectile function: S-(2-boronoethyl)-L-cysteine et al. Endothelial arginase II: A novel target for the treatment of binds to arginase as a transition state analogue and enhances atherosclerosis. Circ Res 2008;102:923-32. smooth muscle relaxation in human penile corpus cavernosum. Biochemistry 2001;40:2678-88. Source of support: Nil; Conflict of interest: None Declared 27. Schade D, Kotthaus J, Clement B. Modulating the NO

Drug Invention Today | Vol 12 • Issue 11 • 2019 2735